Anti-HER2 drug for advanced bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an antibody-drug conjugate that targets HER2 in people with advanced bladder cancer that has spread or cannot be removed by surgery. It is for patients whose cancer has not responded to or stopped responding to platinum-based chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- Your bladder cancer is locally advanced or has spread to other parts of the body
- You have already tried at least one round of platinum-based chemotherapy and it stopped working
- You are able to tolerate the side effects of the study drug (enfortumab vedotin)
- Your tumor tissue can be biopsied for research testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a patient's own tumor cells grown in a lab (organoids) can help doctors choose the best chemotherapy drugs before bladder cancer surgery. It may help find the most effective treatment for you.
This trial tests if using a patient's own tumor cells grown in a lab (organoids) can help choose the best chemotherapy to put directly into the bladder. It is for people with non-muscle invasive bladder cancer who need their first round of this treatment.
This trial uses a lab-grown version of your tumor (an organoid) to see which chemotherapy might work best for you after bladder cancer surgery. It helps doctors choose the most effective treatment for each person.
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
This trial tests a new treatment that uses your own immune cells, called CAR-NK cells, modified to attack two proteins (Nectin-4 and HER2) often found on bladder cancer cells. It is for people whose cancer has spread or cannot be removed by surgery and has not responded to standard treatments like chemotherapy or immunotherapy.
This trial tests a new combination of two medications—one that targets HER2 on cancer cells and one that boosts your immune system—given directly into the bladder. It is for people with high-risk bladder cancer that hasn't spread into the muscle, and who haven't had BCG therapy or for whom BCG didn't work.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.